Gastric cancer remains the third leading cause of cancer-related mortality worldwide, although its incidence has decreased over the past six decades. The identified strongest risk factor for stomach cancer is chronic infection with *Helicobacter pylori*, a kind of genotoxic DNA pathogens[@b1][@b2]. Although current treatments such as surgery and chemotherapy have progressed, most patients are diagnosed at an advanced stage and still carry a dismal prognosis[@b3][@b4]. Therefore, molecular approaches are urgently needed in understanding tumor progression, in discovering novel biomarkers, and in determining effective therapies for use in clinical settings.

STING (stimulator of interferon genes), an endoplasmic reticulum localized protein, has recently been identified as one of the critical adaptors for cytosolic DNA sensing pathway[@b5]. It plays an important role in host defenses against virus and intracellular bacteria via the regulation of type-I IFN signaling and innate immunity[@b6]. STING can bind to cyclic dinucelotides such as cyclic di-AMP, cyclic di-GMP or cyclic di-GMP-AMP produced by virus or bacteria through its globular carboxy-terminal domain, thus facilitating its interaction with the cytosolic kinase TBK1 and inducing the activation of transcription factors IRF3 or STAT6. Then IRF3 or STAT6 translocate into nucleus to induce interferons and other cytokines[@b7]. Recently, several reports revealed the suppressive role of STING in tumorigenesis, including prostate cancer, colorectal carcinoma and melanomas[@b8][@b9][@b10]. However the role of STING in human gastric cancer remains largely unknown.

Considering the infection of *H. pylori* and the genomic DNA released by dying tumor cells[@b11], STING might be involved in the tumorigenesis and progression of gastric cancer. The aim of this study was to evaluate the expression and function of STING in gastric cancer and elucidate its correlation with tumor development and prognosis.

Results
=======

The expression of STING is down-regulated in gastric cancer
-----------------------------------------------------------

To explore the role of STING in the development of gastric cancer, the relative mRNA expression of STING was analyzed in 21 paired gastric cancer samples, and decreased expression of STING was observed in 90.5% cases ([Fig. 1a](#f1){ref-type="fig"}). Western blot analysis revealed that STING protein levels were also remarkably reduced in tumor tissues compared with matched adjacent non-tumor tissues ([Fig. 1a](#f1){ref-type="fig"}). Then a tissue microarray was employed to examine STING expression in 217 gastric cancer patients with different stages. The representative staining of STING in tumor tissues and pericarcinomatous tissues were shown in [Fig. 1b](#f1){ref-type="fig"}. STING was mainly localized in the cell cytoplasm. Furthermore, we found that STING was mostly highly expressed in normal gastric epithelium, and was down-regulated in matched transformed tissues. The expression of STING was also detected in the surrounding stroma in some cases ([Fig. 1b](#f1){ref-type="fig"}). Statistical analysis revealed that STING staining score in tumor cells was significantly lower than that in normal gastric epithelium (*P* \< 0.001) in all patients ([Fig. 1c](#f1){ref-type="fig"}). Moreover, STING staining levels were decreased in both TNM I--II and TNM III--IV subgroups, suggesting that reduced STING expression may manifest in early stage patients with gastric cancer ([Fig. 1c](#f1){ref-type="fig"}).

Correlations between intratumoral STING expression and clinicopathological features in gastric cancer patients
--------------------------------------------------------------------------------------------------------------

We next assessed the correlation between STING expression and clinicopathological features in gastric cancer patients. The high and low expression of intratumoral STING was determined by ROC curve analysis, and the representative images were shown in [Fig. 1d](#f1){ref-type="fig"}. Chi-square analysis demonstrated that low expression of STING in gastric cancer was positively correlated with tumor size (*P* = 0.022), tumor invasion depth (*P* \< 0.001), lymph mode metastasis (*P* = 0.003) and advanced TNM stage (*P* \< 0.001) ([Table 1](#t1){ref-type="table"}). To better understand the role of STING in the progression of gastric cancer, the percentages of high and low expression of STING in different T stage, N stage, M stage and TNM stage were graphically displayed ([Fig. 1e](#f1){ref-type="fig"}). Results demonstrated that the expression of STING was profoundly reduced with the progression of gastric cancer.

Association of intratumoral STING expression with overall survival in gastric cancer patients
---------------------------------------------------------------------------------------------

The association of intratumoral STING expression with overall survival was illustrated by Kaplan-Meier analysis. The results revealed that patients with STING low expression showed poorer overall survival than those with STING high expression (*P* \< 0.001) ([Fig. 2a](#f2){ref-type="fig"}). The overall survival rate of STING low expression group (39.3%) was nearly 2 times lower than the high expression group (75.3%). To further determine whether STING expression could stratify patients with different TNM stage, we grouped the TNM I + II and TNM III + IV as early and advanced stage disease, respectively. Similarly, low expression of STING was associated with shorter overall survival in both subgroups of gastric cancer patients ([Fig. 2b,c](#f2){ref-type="fig"}).

Prognostic factors for gastric cancer patients
----------------------------------------------

The univariate and multivariate analyses were performed to determine the prognostic factors for overall survival in gastric cancer patients. As shown in [Table 2](#t2){ref-type="table"}, patients' tumor size (HR, 1.871; 95% CI, 1.266--2.767; *P* = 0.002), tumor location (HR, 1.828; 95% CI, 1.201--2.782; *P* = 0.005), vessel invasion (HR, 2.411; 95% CI, 1.507--3.855; *P* \< 0.001), tumor invasion depth (HR, 3.947; 95% CI, 2.596--6.000; *P* \< 0.001), lymph node metastasis (HR, 3.124; 95% CI, 2.076--4.701; *P* \< 0.001), distant metastasis (HR, 37.03; 95% CI, 7.487--183.1; *P* \< 0.001), TNM stage (HR, 4.880; 95% CI, 3.298--7.221; *P* \< 0.001), and STING expression (HR, 2.599; 95% CI, 1.752--3.857; *P* \< 0.001) were identified as risk factors that might affect the overall survival of gastric cancer patients. Further estimate by utilizing of multivariate Cox regression analysis demonstrated that tumor invasion depth (HR, 6.186; 95% CI, 1.836--20.846; *P* = 0.003), distant metastasis (HR, 2.812; 95% CI, 1.259--6.283; *P* = 0.012), TNM stage (HR, 2.484; 95% CI, 1.044--5.914; *P* = 0.040), and STING expression (HR, 1.882; 95% CI, 1.136--3.115; *P* = 0.014) were independent predictors for overall survival of gastric cancer patients ([Fig. 3a](#f3){ref-type="fig"}).

Improvement of the TNM staging prognostic model with STING expression
---------------------------------------------------------------------

To establish a more accurate predictive model for outcomes of patients with gastric cancer, STING expression was combined with TNM staging system. The prognostic sensitive and specificity between STING expression with TNM staging system and each of them alone were compared by ROC analysis. Results illustrated that combination of STING expression and TNM staging system showed a significant better prognostic value (AUC, 0.808; 95% CI, 0.750--0.867) than TNM staging alone (AUC, 0.759; 95% CI, 0.694--0.825; *P* \< 0.001), or STING expression alone (AUC, 0.665; 95% CI, 0.593--0.738; *P* \< 0.001) ([Fig. 3b](#f3){ref-type="fig"}). The AIC was reduced from 962.77 to 956.69, and the C-index was increased from 0.764 to 0.775 when the predictive model were created by combing STING expression with TNM staging system than the latter alone ([Fig. 3c](#f3){ref-type="fig"}). All results above indicate that combination STING expression and TNM staging system could generate a more powerful predictive model for overall survival of patients with gastric cancer.

Predictive nomogram for overall survival
----------------------------------------

In addition, a nomogram was constructed to integrate and quantify the proven independent prognostic factors for better outcome prediction. According to the multivariate analysis, TNM stage and STING expression were taken together in this nomogram to improve the accuracy ([Fig. 3d](#f3){ref-type="fig"}). A higher total point indicated a poorer overall survival, and the predicted 3-year and 5-year survival was shown in our data. The performance characteristics for predicting 5-year survival was tested by the calibration plot ([Fig. 3e](#f3){ref-type="fig"}). To further verify the prognostic significance of the nomogram, all patients were divided into three groups (low--risk, medium--risk and high--risk groups) according to the total points of each patient ([Fig. 3d](#f3){ref-type="fig"}), and the result showed that the model could excellently stratified the risk of overall survival of gastric cancer patients ([Fig. 3f](#f3){ref-type="fig"}).

Knock-down of STING promotes the colony formation, viability, migration and invasion of gastric cancer cells
------------------------------------------------------------------------------------------------------------

We next investigated the potential role of STING silencing in tumor characteristics in two kinds of gastric cancer cell lines BGC-823 and SGC-7901 ([Fig. 4a](#f4){ref-type="fig"}). Colony formation and CCK8 assays revealed that knock-down of STING promoted the growth of BGC-823 and SGC-7901 cells *in vitro* ([Fig. 4b,c](#f4){ref-type="fig"}). Moreover, transwell assays demonstrated that gastric cancer cells exhibited a higher migratory and invasive potential when STING expression was reduced ([Fig. 4d--g](#f4){ref-type="fig"}). These data suggest the promotive role of reduced STING expression in cellular processes for tumorigenesis.

Knock-down of STING inhibits the cytosolic DNA sensing and cGAMP-activating effects in gastric cancer cells
-----------------------------------------------------------------------------------------------------------

STING has recently been identified as one of the critical adaptors for cytosolic DNA sensing, followed by the phosphorylation of IRF3 and subsequent production of type-I IFN and IL-6[@b12]. To explore whether STING expression levels correlated with its function, double-stranded DNA (dsDNA) was transfected into gastric cancer cells. Results demonstrated that dsDNA triggered the phosphorylation of IRF3 and the production of IFN-β and IL-6 ([Fig. 5a--c](#f5){ref-type="fig"}). However, these effects were significantly blocked by siRNA-mediated knockdown of STING ([Fig. 5a--c](#f5){ref-type="fig"}). Similar results were also observed upon the stimulation by cGAMP, a well-recognized agonist of STING signaling ([Fig. 5d--f](#f5){ref-type="fig"}). In addition, we also found that dsDNA and cGAMP treatment decreased the protein levels of STING in gastric cancer cells ([Fig. 5a,d](#f5){ref-type="fig"}), probably due to a negative-feedback control of STING activity which was also observed previously[@b13].

*Helicobacter pylori* infection activates STING signaling *in vivo*
-------------------------------------------------------------------

Chronic infection with *H. pylori*, a kind of genotoxic DNA pathogens, is well recognized as a risk factor for gastric cancer. Therefore, we next investigated the effect of *H. pylori* infection on STING signaling *in vivo*. After exposure to *H. pylori* for 20 weeks, STING expression, as well as IRF3 phosphorylation, was up-regulated in gastric epithelial cells, while little change was observed in the expression of IRF3 ([Fig. 6a,b](#f6){ref-type="fig"}). Statistical analysis also confirmed the positive correlation of STING expression with IRF3 phosphorylation in the gastric epithelium of *H. pylori* infected mice ([Fig. 6c](#f6){ref-type="fig"}). In addition, *H. pylori* infection also induced the mRNA expression of IFN-β and IL-6 in the stomach tissues of mice ([Fig. 6d](#f6){ref-type="fig"}). These results indicate that *H. pylori* infection could activate STING signaling in stomach epithelium *in vivo*.

Discussion
==========

Traditional predictive model for outcomes of patients with gastric cancer mainly relies on TNM staging system including the information derived from tumor cell invasion depth, lymph node metastasis and distant metastasis. However, its ability to distinguish a subset of patients is limited due to the heterogeneity of tumor. Therefore, identifying new molecules associated with tumorigenesis in tumor cells would be helpful in understanding the progression of gastric cancer. STING has been extensively studied since the discovery of its participation in the detection of cytosolic DNA species[@b14]. Many kinds of DNA viruses including Hepatitis B Virus (HBV), Cytomegalovirus and Herpes Simplex Virus (HSV) as well as retroviruses such as Human Immunodeficiency Virus (HIV) can be negatively regulated by this innate immune pathway via the activation of interferon response[@b15][@b16][@b17][@b18]. Additionally, a diversity of bacterial infections and autoimmune diseases may also be associated with the modulation of the DNA sensing pathway[@b19][@b20]. Our present study is the first report to clarify the role of STING in the development of gastric cancer. And results indicated that loss of STING was positively associated with tumor progress which possibly due to its reduced function in DNA sensing, and STING could be regarded as a potential prognostic marker for gastric cancer patients.

Recently, accumulating studies have demonstrated the involvement of STING in immune surveillance in human cancers. Defective expression of STING was found in tumor tissues of colorectal carcinoma patients and peripheral blood mononuclear cells of HBV infected patients[@b9][@b21]. STING deficient mice also showed shorter survival when bearing with tumors[@b22]. Since gastric mucosa is the first line to defend foreign pathogens, high expression of STING in normal gastric epithelial cells ([Fig. 1a,b](#f1){ref-type="fig"}) is likely to be required for in maintaining gastric homeostasis. Interestingly, *H. pylori* infection further up-regulated STING expression and activated STING signaling ([Fig. 6](#f6){ref-type="fig"}), which implied that STING might play a role in *H. pylori*-induced chronic gastric inflammation. Nevertheless, we found that dsDNA and cGAMP stimulation could also activate STING signaling but caused the reduction in STING expression ([Fig. 5a,d](#f5){ref-type="fig"}). In sight of these findings, we assume that direct DNA sensing, while activate STING signaling, might reduce STING expression probably in a negative feedback manner. And during the process of chronic *H. pylori* infection, other factors rather than DNA sensing could induce STING expression possibly for a sustained production of inflammatory cytokines. Though *H. pylori* infection has been recognized as a risk factor of gastric carcinogenesis, our data clearly indicated that STING expression was down-regulated in gastric cancer tissues ([Fig. 1](#f1){ref-type="fig"}). Therefore, the decreased expression of STING in gastric cancer is unlikely to be directly caused by *H. pylori* infection, but might be critical for the tumor development through restraining immune surveillance.

The regulations of STING expression have also been studied. The ULK1 kinase which phosphorylated STING at S366, as well as E3 ubiquitin ligase TRIM30α and RNF5, were verified as negative regulators of STING by promoting its degradation[@b12][@b13][@b23]. Conversely, the processing body-associated protein LSm14A was required for the transcription and stability of STING[@b24]. In addition, analysis of STING SNPs data revealed that three non-synonymous SNPs, R71H-G230A-R293Q (HAQ), occur in approximately 20% of the population, but these variants did not obviously alter STING expression and/or stability[@b25][@b26]. Epigenetic processes are also likely to be the cause for reduced STING expression in gastric cancer patients. A recent study demonstrated the presence of considerable CpG islands within the STING promoter region[@b27], and DNA hypermethylation might contribute to the suppressed STING expression in gastric cancer. These studies may provide clues to better understanding how the expression STING is deceased in tumor tissues.

Dynamic regulation of cytokines is the main way of STING to perform its function. Multifarious cytokines will be produced following the activation of STING signaling pathway, and subsequently recruit immune cells to microenvironment. Type-I IFNs have been identified as the major effector in STING-mediated anti-tumor immunity[@b28]. It is reported that type-I IFNs is essential for the maturation of CD11c^+^ CD8α^+^ DCs, and these DCs are critical for induction of tumor-reactive T-cell responses. Neutrophils were also shown to be polarized with type I interferons into anti-tumor N1 phenotype[@b29][@b30]. Type-I IFNs also contributes to the anti-tumor function of NK cells and macrophages[@b31]. Besides, other cytokines could also be regulated by STING, for example, IL-6 is responsible for the production of neutrophils, supports the growth of B cells and is antagonistic to regulatory T cells[@b32]. IL-12 leads to proliferation and activation of CD8^+^ T cells[@b33], and CXCL10 may chemo-attract several kinds of immune cells[@b34]. Reduced STING expression rendered gastric cancer cells a defective function to produce type I interferon and other immune cytokines such as IL-6 after exposure to cytosolic DNA or its agonist cGAMP ([Fig. 5](#f5){ref-type="fig"}). Hence, loss of STING may not only contribute to the *H. pylori* invasion and expansion in gastric mucosa, but also result in the defect of anti-tumor immunity in the process of gastric tumorigenesis. STING might also play a role in influencing the anti-tumor effects of checkpoint inhibitors such as CTLA4 and PD1[@b35]. Lei Jin *et al*. revealed a novel function of STING in regulating monocyte migration that was distinct from its role in activating cytokines production[@b36]. On the other hand, activation of STING could directly induce cell apoptosis and autophagy in malignant cells[@b37][@b38], which might shape the inhibition of tumor growth.

In addition to its intratumoral staining, STING was detected in stroma in some cases of gastric cancer patients ([Fig. 1b](#f1){ref-type="fig"}). By the present study, it remains to be determined whether STING expression in this place was associated with the progression of gastric cancer. However, extrinsic STING activity in tumor microenvironment apart from the tumor cells was also likely to play a critical role in the immune surveillance of tumor cells[@b39]. Overall, the profound molecular roles of STING signaling in gastric cancer remain far from being fully elucidated and need further investigation.

In conclusion, low STING expression was an independent and adverse predictor of overall survival in gastric cancer patients. And a more accurate predictive model for outcomes could be established by combining STING expression and TNM staging system. Knock-down of STING promoted colony formation, viability, migration and invasion in gastric cancer cells, and also led to a defect in cytosolic DNA sensing. Thus, STING might be a new biomarker for gastric cancer prognosis, and targeting STING with its agonist may provide novel approach for the immunotherapeutic treatment of gastric cancer.

Materials and Methods
=====================

Patient Samples
---------------

All of the methods were approved by the research medical ethics committee of Fudan University and were performed in accordance with the approved guidelines. Tumor and matched peritumoral specimens were obtained from 217 gastric cancer patients who underwent surgical resection without preoperative treatment from 2004 to 2008, at the Department of General Surgery, Zhongshan Hospital (Fudan University, Shanghai, China). Another independent group of 21 paired frozen gastric cancer and matched normal mucosa tissues was also collected at the Department of General Surgery, Zhongshan Hospital (Fudan University, Shanghai, China) in the year 2014. The diagnosis of gastric cancer was confirmed by pathologic examination. Patients' clinicopathological characteristics, date of surgery, tumor stage, Lauren's type, tumor location, surgical treatment methods, survival time, and other relevant clinicopathological data were obtained from hospital records. The use of human tissue samples and clinical data was approved by the Research Ethics Committee of Zhongshan Hospital. Informed consent was obtained from all patients.

Animal Studies
--------------

Five to six-week-old male C57BL/6 mice were purchased from Shanghai Laboratory Animal Center of Chinese Academy Sciences and housed in a separate pathogen-free room. Animal care and experiments were performed in strict accordance with the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health, and approved by the ethics committee of Fudan University. Mouse model of chronic *H. pylori* infection was established as described previously[@b40]. Briefly, each mouse was intragastrically administered with 1 × 10^8^ CFU *H. pylori* SS1 cells in 200 μl broth medium, while mice in the control group were intragastrically given with 200 μl broth medium, once every other day for 3 times. After 20 weeks, mice from both model group and control group were sacrificed and stomach tissues were collected for further analysis.

Cell Lines
----------

Human gastric cancer cell lines BGC-823 and SGC-7901 were obtained from Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China). Both cells were cultured in Dulbecco's modified Eagle's medium replenished with 10% FBS (Gibco, Grand Island, NY, USA), and cultured at 37 °C in a humidified 5% CO2 incubator.

Western Blot
------------

Briefly, polyacrylamide gel electrophoresis was used to separate proteins which extracted from tissues or cells, and transferred onto polyvinylidene fluoride membranes. Membranes were incubated with primary antibodies including: STING (1:1000; Proteintech, Chicago, IL, USA), IRF3 (1:1000; Proteintech), p-IRF3 (1:1000; Cell Signaling, Boston, MA, USA), GAPDH (1:3000; Proteintech), and then with HRP-conjugated secondary antibody. At last, enhanced chemiluminescence assay was used to detect the reactions.

Real-time PCR
-------------

Total RNA was purified from stomach tissues or cancer cells using TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The RNA was then processed for reverse transcription and quantitative PCR using a Takara RNA PCR Kit and SYBR Premix Ex Taq (Takara, Tokyo, Japan) in accordance with the manufacturer's instructions. GAPDH was used as an internal control. The primers used were as follows: Human STING, sense: CCTGAGTCTCAGAACAACTGCC, anti-sense: GGTCTTCAAGCTGCCCACA-GTA; Human IFN-β, sense: AGGACAGGATGAACTTTGAC, anti-sense: TGATAGACATTAGCCAGGAG; Human IL-6, sense: AGACAGCCACTCACCT- CTTCAG, anti-sense: TTCTGCCAGTGCCTCTTTGCTG; Human GAPDH, sense: GAGTCAACGGATTTGGTCGT, anti-sense: TTGATTTTGGAGGGATCTCG; Mouse IFN-β, sense: TCCGAGCAGAGATCTTCAGGAA, antisense: TGCAACCA-CCACTCATTCTGAG; Mouse IL-6, sense: TCCAGTTGCCTTCTTGGGAC, anti-sense: GTGTAATTAAGCCTCCGACTTG; Mouse GAPDH, sense: GAGCGAGACCCCACTAACAT, anti-sense: TCTCCATGGTGGTGAAGACA.

Tissue microarray construction and immunohistochemistry
-------------------------------------------------------

Tissue microarray construction was carried out as previous described[@b41]. Primary antibody was used for IHC staining. In brief, the tissue microarrays were baked at 60 °C for 6 h, dewaxed in xylene, rehydrated through a gradient concentration and blocked the endogenous peroxidase activity by 3% hydrogen peroxide. After antigen retrieving by citrate buffer using microwave oven, the sections were incubated with the primary antibody including STING (1:200 dilution), IRF3 (1:100 dilution), p-IRF3 (1:100 dilution) at 4 °C overnight. Then, tissue sections were treated with Primary Antibody Amplifier Quanto and HRP Polymer Quanto (Thermo Scientific, Fremont, CA, USA). Finally, the sections were visualized by DAB solution and counterstained with haematoxylin. IHC staining score was assessed by two independent pathologists who were blinded to the patients' clinicopathological data. The score for the extent of the IHC-stained area was set as 0 for \<5%; 1 for 5--25%; 2 for 26--50%; 3 for 51--75%; and 4 for 76%--100% of tumor cells stained. The score for IHC intensity was also scaled as 0 for no IHC signal, 1 for weak, 2 for moderate, and 3 for strong. The final score used in the analysis was calculated by multiplying the extent score and intensity score, with a series of results ranging from 0 to 12. Values less than or equal to 6 were considered as the low expression, based on Receiver Operating Characteristic (ROC) analysis.

siRNA, dsDNA transfection, and cGAMP treatment
----------------------------------------------

The targeting sequence for STING siRNA was: 5′-CCTCATCAGTGGAATG-GAA-3′, according to a previous report[@b7]. Transfection of siRNA into gastric cancer cells was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions.

The dsDNA was prepared from equimolar amounts of the sense and antisense DNA oligonucleotide (sense strand sequence: 5′-TACAGATCTACTAGTGATCTAT-GACTGATCTGTACATGATCTACA-3′). The oligonucleotides in annealing buffer (Beyotime Biotechnology, Shanghai, China) were heated at 95 °C for 5 min and cooled to room temperature. Transfection of dsDNA into gastric cancer cells was also carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions.

For cGAMP treatment, cGAMP (2 μg/ml) purchased from Invivogen (San Diego, CA, USA) was added to cells at 37 °C in a permeabilization buffer (50 mM HEPES, 100 mM KCl, 3 mM MgCl~2~, 85 mM sucrose, 0.1 mM DTT, 0.2% BSA, 1 mM ATP, 10 mg/ml digitonin) as described earlier[@b42] and medium was replaced 30 min later. Then cells were harvested 3 hours post-treatment.

Cell colony formation, viability and transwell assays
-----------------------------------------------------

Gastric cancer cells were transfected as indicated. 48 h later, cells were used to perform the following assays. For colony formation assays, 1 × 10^3^ cells were seeded in 6-well plates. After culture for 10 days, cell colonies were fixed with paraformaldehyde (4%), stained with 0.1% crystal violet, and photographed using a digital camera. Colonies which contained 50 or more cells were counted. All experiments were performed at least three times.

For CCK8 assays, Cell Counting Kit-8 (DOJINDO, Kumamoto, Japan) was used to determine cell viability. Briefly, transfected cells were seeded in 96-well plates (3,000 cells per well), and cultured for the indicated times, then incubated with Cell Counting Kit-8 for 1 h. Absorbance was measured at 450 nm with a Universal Microplate Reader (Bio-Tek Instruments, Winooski, VT, USA). Three independent repeats were performed in all assays.

Transwell migration and invasion assays were performed in 12-well transwell plates (8 μm pore size) according to the manufacturer's instructions (Corning, New York, NY, USA). For invasion assays only, the bottom of transwell chamber was coated with BD Matrigel Basement Membrane Matrix (BD Biosciences, San Diego, CA, USA). 1 × 10^5^ cells in basic culture medium without serum were added into the upper chamber, and the lower chamber was filled with culture medium containing 20% FBS as a chemo-attractant. Migration and invasion of cells were determined 24 h and 48 h later, respectively. Cells on the upper side of the chamber were removed from the surface of the membrane by scrubbing, and cells on the lower surface of the membrane were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The number of infiltrating cells was counted in five randomly selected microscopic fields of each filter.

Statistical Analysis
--------------------

Analysis was performed with SPSS 22.0 (IBM Corporation, Armonk, NY, USA), GraphPad Prism 5 (GraphPad software, La Jolla, CA, USA), Stata 12.0 (Stata CorpLP, College Station TX, USA), and R software version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria). The relationships between clinical variables and STING expression was analyzed by Pearson χ^2^ test. Kaplan-Meier method was used to determine the overall survival and log-rank test was used to compare overall survival curve between different subgroups. Independent associations between overall survival and assessed clinicopathological predictors were evaluated by multivariate Cox proportional hazards regression models. Differences between two groups were examined by Student's two-tailed *t*-test. Furthermore, R software was utilized to establish a nomogram and the predictive accuracy of this nomogram was tested by calibration plots. Correlation between two groups was analyzed using nonparametric Spearman's r test. All statistical significance was set at two-sided and the *P* value was less than 0.05.
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![STING expression is down-regulated in gastric cancer and correlated with tumor progression.\
(**a**) The mRNA levels of STING in 21 cases of gastric cancer and paired adjacent non-tumor tissues were determined by real-time PCR analysis (top). And protein levels in 7 cases of gastric cancer and paired adjacent non-tumor tissues were determined by western blot analysis (bottom). N, adjacent non-tumor tissues; T, matched gastric cancer tissues. (**b**) Representative IHC staining of STING in tumor tissue and matched non-tumor tissue of gastric cancer patients. STING staining was mostly detected in cell cytoplasm. And STING was highly expressed in normal gastric epithelium, and was down-regulated in matched tumor tissues. The expression of STING was also detected in the surrounding stroma in some cases. (**c**) The staining score of tumor tissues comparing with normal tissues in all patients, TNM I-II subgroup, and TNM III-IV subgroup, respectively. (**d**) The representative low and high expression of STING in tumor tissues. (**e**) The relative proportion of patients with high STING expression is decreased with tumor progression in gastric cancer.](srep39858-f1){#f1}

![Kaplan-Meier analysis for overall survival of gastric cancer patients according to STING expression.\
The association of STING relative low and high expression in tumor tissues with overall survival was examined by Kaplan--Meier analysis, (**a**) in all patients; (**b**) in patients at TNM I+II stage; (**c**) in patients at TNM III+IV stage.](srep39858-f2){#f2}

![STING expression is an independent factor that could be combined with TNM stage for better prognostic prediction in gastric cancer patients.\
(**a**) Multivariate Cox analysis was performed to identify independent prognostic factors in patients with gastric cancer. (**b**) ROC analysis of the sensitivity and specificity for the predictive value of TNM model, STING expression model and the combined model. (**c**) The predictive accuracies of TNM staging, STING expression and the combined model were compared by AIC and C-index. Another prognostic predicting model nomogram was builted for overall survival in gastric cancer patients. (**d**) Nomogram was utilized to quantify the integrated effect of the proven independent prognostic factors for overall survival. (**e**) Calibration plot of the nomogram for 5-year survival. (**f**) Of all 217 patients, three groups were divided according to the total points in the nomogram which range of 0--30, 31--90, 91--120, was refined as low---, medium--- and high---risk subgroup, respectively. Kaplan--Meier analysis was used to test the correlation of the risk with overall survival.](srep39858-f3){#f3}

![Knock-down of STING promotes the colony formation, viability, migration and invasion of gastric cancer cells.\
(**a**) The knock-down efficiency of STING siRNA in BGC-823 and SGC-7901 cells was monitored by western blot and real-time PCR. (**b**) Colony formation assays of BGC-823 and SGC-7901 cells transfected with STING siRNA or scrambled control siRNA. (**c**) The effects of STING knock-down on cell viabilities were examined by CCK8. (**d--g**) Transwell assays was employed to determine the influence of STING silencing on the migratory (**d,e**) and invasive (**f,g**) abilities in BGC-823 and SGC-7901 cells.](srep39858-f4){#f4}

![Knock-down of STING inhibits the cytosolic DNA sensing and cGAMP-activating effects in gastric cancer cells.\
(**a--c**) BGC-823 and SGC-7901 cells with or without STING depletion were transfected with dsDNA (4 μg/ml), and the expression level of STING and phosphorylation of IRF3 were then measured by western blot (**a**). IFN-β (**b**) and IL-6 (**c**) mRNA levels were measured by real-time PCR. (**d--f**) BGC-823 and SGC-7901 cells with or without STING depletion were stimulated with cGAMP (2 μg/ml), and the expression level of STING and phosphorylation of IRF3 were then measured by western blot (**d**). IFN-β (**e**) and IL-6 (**f**) mRNA levels were measured by real-time PCR.](srep39858-f5){#f5}

![*Helicobacter pylori* infection activates STING signaling *in vivo*.\
Mouse model of chronic *H. pylori* infection was established as described in the "Materials and Methods". (**a**) The expression pattern of STING and its downstream IRF3 phosphorylation in gastric epithelium were examined by IHC staining, and the representative images were shown. (**b**) The IHC staining scores of STING, IRF3 and p-IRF3 were compared between model group and control group. (**c**) Correlation analysis between STING expression and IRF3/p-IRF3 levels in *H. pylori*-infected mice. (**d**) The mRNA levels of IFN-β and IL-6 in stomach tissues were compared between model group and control group.](srep39858-f6){#f6}

###### Relationship between STING expression and clinicopathological characteristics in patients with gastric cancer.

  Factors                      No.      STING expression    P-value   
  ------------------------- ---------- ------------------ ----------- -------------
  Gender                                                              
   Male                        144         97 (67.4)       47 (32.6)      0.219
   Female                       73         43 (58.9)       30 (41.1)         
  Age (years)                                                         
   \<60                        102         64 (62.7)       38 (37.3)      0.608
   ≥60                         115         76 (66.1)       39 (33.9)         
  Tumor size (cm)                                                     
   Mean                        3.8            4.1             3.4       **0.022**
   Median                      3.5            4.0             3.0            
   IQR                       2.0--6.0       2.0--6.0       1.5--5.0          
  Tumor location                                                      
   Upper third                  36         26 (72.8)       10 (27.2)      0.462
   Middle third                 37         25 (67.6)       12 (32.4)         
   Lower third                 144         89 (61.8)       55 (38.2)         
  Lauren's classification                                             
   Intestinal                  136         92 (67.6)       44 (32.4)      0.669
   Diffuse                      54         35 (64.8)       19 (35.2)         
   Mixture                      17         13 (76.5)       4 (23.5)          
  Differentiation                                                     
   Poorly differentiated       183         121 (66.1)      62 (33.9)      0.252
   Well differentiated          34         19 (55.9)       15 (44.1)         
  Vessel invasion                                                     
   Absent                      159         97 (61.0)       62 (39.0)      0.074
   Present                      58         43 (74.1)       15 (25.9)         
  Tumor invasion depth                                                
   T1                           38         13 (34.2)       25 (65.8)   **\<0.001**
   T2                           15          8 (53.3)       7 (46.7)          
   T3                           65         47 (72.3)       18 (27.7)         
   T4                           99         72 (72.7)       27 (27.3)         
  Lymph node metastasis                                               
   N0                           60         29 (48.3)       31 (51.7)    **0.003**
   N1                           37         21 (56.8)       16 (43.2)         
   N2                           43         31 (72.1)       12 (27.9)         
   N3                           77         59 (76.6)       18 (23.4)         
  Distant metastasis                                                  
   Absent                      210         134 (63.8)      76 (36.2)      0.233
   Present                      7           6 (85.7)       1 (14.3)          
  TNM stage                                                           
   I                            36         14 (38.9)       22 (61.1)   **\<0.001**
   II                           56         31 (55.4)       25 (44.6)         
   III                         118         89 (75.4)       29 (24.6)         
   IV                           7           6 (85.7)       1 (14.3)          

TNM = tumor node metastasis; IQR = inter quartile range. *P*-value \< 0.05 marked in bold font shows statistical significant.

###### Univariate Cox regression analysis of clinicopathological characteristics influencing the overall survival of gastric cancer patients.

  Factors                                Univariate                 
  ------------------------------------- ------------ -------------- -------------
  Gender                                                            
   Male *vs.* female                       1.451      0.970--2.170      0.070
  Age (years)                                                       
   ≥ 60 *vs.* \<60                         1.258      0.854--1.853      0.246
  Tumor size (cm)                                                   
   \>3.5 *vs.* ≤3.5                        1.871      1.266--2.767    **0.002**
  Tumor location                                                    
   Upper + middle *vs.* lower              1.828      1.201--2.782    **0.005**
  Lauren's classification                                           
   Diffuse + mixture *vs.* intestinal      1.365      0.898--2.076      0.145
  Differentiation                                                   
   Poorly *vs.* well                       1.038      0.611--1.762      0.891
  Vessel invasion                                                   
   Present *vs.* absent                    2.411      1.507--3.855   **\<0.001**
  Tumor invasion depth                                              
   T3 + T4 *vs.* T1 + T2                   3.947      2.596--6.000   **\<0.001**
  Lymph node metastasis                                             
   N1 + N2 + N3 *vs.* N0                   3.124      2.076--4.701   **\<0.001**
  Distant metastasis                                                
   Present *vs.* absent                    37.03      7.487--183.1   **\<0.001**
  TNM stage                                                         
   III + IV *vs.* I + II                   4.880      3.298--7.221   **\<0.001**
  STING expression                                                  
   Low *vs.* high                          2.599      1.752--3.857   **\<0.001**

95% CI = 95% confidence interval; HR = hazard ratio; TNM = tumor node metastasis. *P*-value \< 0.05 marked in bold font shows statistically significant.

[^1]: These authors contributed equally to this work.
